Roffman Miller Associates Inc. PA cut its stake in GlaxoSmithKline PLC (NYSE:GSK) by 20.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,169 shares of the pharmaceutical company’s stock after selling 1,788 shares during the period. Roffman Miller Associates Inc. PA’s holdings in GlaxoSmithKline PLC were worth $309,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the company. Pekin Singer Strauss Asset Management IL raised its stake in GlaxoSmithKline PLC by 1.1% in the first quarter. Pekin Singer Strauss Asset Management IL now owns 5,516 shares of the pharmaceutical company’s stock valued at $233,000 after buying an additional 60 shares during the last quarter. Court Place Advisors LLC raised its stake in GlaxoSmithKline PLC by 1.0% in the first quarter. Court Place Advisors LLC now owns 8,481 shares of the pharmaceutical company’s stock valued at $358,000 after buying an additional 84 shares during the last quarter. Park National Corp OH raised its stake in GlaxoSmithKline PLC by 1.9% in the first quarter. Park National Corp OH now owns 6,314 shares of the pharmaceutical company’s stock valued at $266,000 after buying an additional 118 shares during the last quarter. NEXT Financial Group Inc raised its stake in GlaxoSmithKline PLC by 0.9% in the second quarter. NEXT Financial Group Inc now owns 13,396 shares of the pharmaceutical company’s stock valued at $578,000 after buying an additional 118 shares during the last quarter. Finally, Camelot Portfolios LLC raised its stake in GlaxoSmithKline PLC by 0.6% in the first quarter. Camelot Portfolios LLC now owns 20,786 shares of the pharmaceutical company’s stock valued at $876,000 after buying an additional 120 shares during the last quarter. 8.96% of the stock is currently owned by institutional investors and hedge funds.
GlaxoSmithKline PLC (NYSE GSK) traded down 1.10% on Monday, reaching $40.48. 4,017,530 shares of the company’s stock were exchanged. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $45.58. The stock’s 50 day moving average is $42.84 and its 200 day moving average is $41.78. The company has a market cap of $98.93 billion, a price-to-earnings ratio of 39.92 and a beta of 1.05.
GlaxoSmithKline PLC (NYSE:GSK) last announced its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The business had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. On average, equities analysts anticipate that GlaxoSmithKline PLC will post $2.84 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be issued a $0.491 dividend. The ex-dividend date is Wednesday, August 9th. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 annualized dividend and a yield of 4.80%. GlaxoSmithKline PLC’s dividend payout ratio is presently 194.00%.
ILLEGAL ACTIVITY WARNING: This article was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://stocknewstimes.com/2017/07/31/roffman-miller-associates-inc-pa-reduces-stake-in-glaxosmithkline-plc-nysegsk-updated.html.
A number of equities research analysts have commented on the stock. Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, July 21st. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Monday, July 24th. BidaskClub lowered shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. TheStreet lowered shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a report on Wednesday, July 26th. Finally, Citigroup Inc. reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the stock. GlaxoSmithKline PLC has an average rating of “Hold” and a consensus price target of $46.00.
About GlaxoSmithKline PLC
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.
